Yourgene Health to Acquire Elucigene for £9.2M in Cash, Stock

Apr 17, 2019

|

NEW YORK (GenomeWeb) — UK molecular diagnostics firm Yourgene Health said today that it has agreed to acquire Elucigene for £9.2 million ($12.0 million) in cash and stock in a bid to bolster its presence in the noninvasive prenatal testing (NIPT) market.

To fund the transaction, Yourgene said it is planning to raise at least £10.0 million through the sale of roughly 97.5 million newly issued shares.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Delivering Precision Health: the Role of Molecular Diagnostics

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

25

Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu